MAST CELL IMMUNOMETABOLISM IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: UNRAVELING MECHANISMS AND THERAPEUTIC OPPORTUNITIES
Scientific Records · 07.08.2026 · 156
DOI: 10.62324/journal.sr/2026.076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Records, online erschienen am 07.08.2026.
Abstract (Originalsprache)
Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive malignancies worldwide, with limited therapeutic options and poor prognosis despite advances in surgery, chemoradiotherapy, and immunotherapy.The tumor microenvironment (TME) of ESCC is characterized by profound metabolic reprogramming and immune dysfunction, which collectively drive tumor progression and therapeutic resistance.Mast cells (MCs), traditionally recognized as allergic effector cells, have emerged as critical yet understudied modulators of the ESCC TME.Recent single-cell and spatial transcriptomic analyses have revealed substantial MC heterogeneity, identifying distinct subsets including lipid-enriched, immunosuppressive, hypoxia-associated, and pro-inflammatory populations.These MC subsets actively shape tumor metabolism through the release of lipid mediators' prostaglandins, leukotrienes, and platelet-activating factor that amplify lipid metabolic programs in tumor cells while establishing an immunosuppressive niche.MC-derived cytokines and proteases further remodel the extracellular matrix and facilitate immune evasion by impairing dendritic cell function, promoting regulatory T cell expansion, and inducing CD8+ T cell exhaustion.Emerging evidence implicates MCs in epigenetic reprogramming of cancer cells and stromal fibroblasts through TGF-β, PGE2, and tryptasemediated signaling.This review synthesizes current evidence on MC-driven immunometabolism in ESCC, highlighting MC heterogeneity, metabolic reprogramming mechanisms, immune evasion pathways, and epigenetic regulation.We propose a framework positioning MCs as upstream coordinators of immunometabolism remodeling and identify therapeutic opportunities targeting MC mediators, lipid metabolic enzymes, and epigenetic modifiers.The integration of MC-directed strategies with immune checkpoint inhibition represents a promising approach to overcome resistance and improve outcomes in ESCC.
Zitieren
APA
(2026). MAST CELL IMMUNOMETABOLISM IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: UNRAVELING MECHANISMS AND THERAPEUTIC OPPORTUNITIES. Scientific Records, 156. https://doi.org/10.62324/journal.sr/2026.076
Vancouver
MAST CELL IMMUNOMETABOLISM IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: UNRAVELING MECHANISMS AND THERAPEUTIC OPPORTUNITIES. Scientific Records. 2026:156. doi:10.62324/journal.sr/2026.076
BibTeX
@article{euvimed2026,
title = {MAST CELL IMMUNOMETABOLISM IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: UNRAVELING MECHANISMS AND THERAPEUTIC OPPORTUNITIES},
journal = {Scientific Records},
year = {2026},
pages = {156},
doi = {10.62324/journal.sr/2026.076}
}
EUVIMED